Insilico Medicine (‘Insilico’), a clinical-stage generative artificial intelligence (AI)-driven drug discovery and development company, today announces positive results from two Phase I studies in Australia and China of ISM5411, a novel gut-restricted and PHD specific Inhibitor designed and optimized with the support of Insilico’s Chemistry42 commercially-available generative reinforcement learning platform, for Inflammatory Bowel Disease (IBD).
Which drugs are most likely to be approved in Primary Mediastinal B-Cell Lymphoma?
Primary Mediastinal B-Cell Lymphoma disease is an indication for drug development with over 140 pipeline drugs currently active according to GlobalData.
March 28, 2024